{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T17:01:47Z","timestamp":1779987707155,"version":"3.53.1"},"reference-count":13,"publisher":"S. Karger AG","issue":"3","license":[{"start":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T00:00:00Z","timestamp":1751673600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T00:00:00Z","timestamp":1751673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Haematol"],"abstract":"<jats:p>&lt;p&gt;Introduction: Myeloid\/lymphoid neoplasms with fibroblast growth factor receptor 1 rearrangement (MLN-FGFR1) are rare, heterogenous, aggressive hematologic malignancies with FGFR1 rearrangements at the 8p11 locus. Pemigatinib, a potent selective inhibitor of FGFR1-3, is approved for relapsed\/refractory MLN-FGFR1. Methods: This retrospective chart review included US adults with myeloproliferative neoplasm, unclassifiable (MPN-U), myelodysplastic syndrome (MDS)\/MPN, post-MPN acute myelogenous leukemia, precursor T- or B-cell acute lymphoblastic leukemia\/lymphoma, or mixed-phenotype acute leukemia with bone marrow biopsy and standard cytogenetic and\/or molecular results. Probable cases of MLN-FGFR1 were identified and confirmed with cytogenetic or molecular testing results. Patient characteristics, diagnostic testing methods, treatments, and outcomes were abstracted. Results: Of 560 submitted cases, 51 (9.1%) were probable MLN-FGFR1, 33 (5.9%) of which were subsequently confirmed. Among patients with confirmed MLN-FGFR1, 8p11 translocation or FGFR1 rearrangements were detected with standard cytogenetics in 72.7%, break-apart fluorescence in situ hybridization in 66.7%, next-generation sequencing in 21.2%, and real-time polymerase chain reaction in 6.1%. All but 1 patient initiated treatment; 3 patients underwent allogenic stem-cell transplant. Conclusion: This study highlights the importance of cytogenetic and molecular evaluations in patients with chronic\/blast phase hematologic malignancies to diagnose MLN-FGFR1. This is particularly important following US approval of pemigatinib for this hematologic malignancy. &lt;\/p&gt;<\/jats:p>","DOI":"10.1159\/000546910","type":"journal-article","created":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T12:02:28Z","timestamp":1751716948000},"page":"252-262","source":"Crossref","is-referenced-by-count":1,"title":["Identification and Confirmation of Myeloid\/Lymphoid Neoplasms with Fibroblast Growth Factor Receptor 1 Rearrangement and Characterization of Treatment Patterns and Outcomes in a Real-World Setting: A US Retrospective Chart Review"],"prefix":"10.1159","volume":"149","author":[{"given":"Shreekant","family":"Parasuraman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3421-3755","authenticated-orcid":false,"given":"Kimberly","family":"Saverno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin M.","family":"Zimmerman Savill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philomena","family":"Colucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2025,7,5]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1015792"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0404438101"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v126.23.2812.2812"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.20517\/cdr.2021.30"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01613-1"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1080\/10245332.2018.1446279"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2009.11.003"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2010.03.035"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2022.03.008"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0231877"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S189391"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-10-695973"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-163099"}],"container-title":["Acta Haematologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000546910","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T16:02:10Z","timestamp":1779984130000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000546910"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,5]]},"references-count":13,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,5,28]]},"published-print":{"date-parts":[[2026,5,28]]}},"URL":"https:\/\/doi.org\/10.1159\/000546910","archive":["Portico"],"relation":{},"ISSN":["0001-5792","1421-9662"],"issn-type":[{"value":"0001-5792","type":"print"},{"value":"1421-9662","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,5]]}}}